Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"StrideBio","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","amount":"$81.5 million","upfrontCash":"Undisclosed","newsHeadline":"StrideBio Announces Closing of $81.5M Series B Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"StrideBio","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio's AAV Capsid Discovery and Engineering Platform Assets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by StrideBio

    Menu

    StrideBio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              StrideBio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ginkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio's AAV Capsid Discovery and Engineering Platform Assets

              Details:

              The addition of StrideBio's structure-guided AAV engineering capabilities combined with Ginkgo's already extensive assets make Ginkgo a unique one-stop shop capable of providing R&D services for gene therapy manufacturing across capsid, payload, and cell line optimization.

              Lead Product(s): AAV-based Gene Therapy

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Ginkgo Bioworks

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition April 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              StrideBio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              StrideBio Announces Closing of $81.5M Series B Financing

              Details:

              Proceeds to advance structure-guided AAV capsid engineering platform and pipeline of novel gene therapy candidates into the clinic, including four new wholly-owned programs.

              Lead Product(s): STRX-310

              Therapeutic Area: Neurology Product Name: STRX-310

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Northpond Ventures

              Deal Size: $81.5 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing March 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY